GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q2 FY23 results · Jul–Sep 2022
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹916.87 crore (down 9.2% from Q2 FY22) and net profit of ₹193.42 crore (down 5.3% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 916.87 | 1,009.87 | −9.2% | 745.10 | +23.1% |
| Other income | 21.97 | 14.97 | +46.8% | 27.61 | −20.4% |
| Total income | 938.84 | 1,024.84 | −8.4% | 772.71 | +21.5% |
| Profit before tax | 262.15 | 273.54 | −4.2% | 160.03 | +63.8% |
| Net profit for the period | 193.42 | 204.24 | −5.3% | 119.28 | +62.2% |
| EPS, basic (₹) | 11.42 | 12.06 | −5.3% | 7.04 | +62.2% |
| Net margin (%) | 21.1 | 20.2 | 16.0 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 905.61 | 991.53 | −8.7% | 729.46 | +24.1% |
| Other income | 22.16 | 15.05 | +47.2% | 27.79 | −20.3% |
| Total income | 927.77 | 1,006.58 | −7.8% | 757.25 | +22.5% |
| Profit before tax | 262.33 | 271.49 | −3.4% | 159.22 | +64.8% |
| Net profit for the period | 193.56 | 202.65 | −4.5% | 118.68 | +63.1% |
| EPS, basic (₹) | 11.42 | 11.96 | −4.5% | 7.01 | +62.9% |
| Net margin (%) | 21.4 | 20.4 | 16.3 |
Consolidated
- Filed with BSE
- 12 Nov 2022, 12:47 IST
- Board meeting
- 11 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Nov 2022, 12:47 IST
- Board meeting
- 11 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE